Cyto-Reductive Surgery (CRS) with Hyperthermic Intra-Peritoneal Chemotherapy (HIPeC) improves survival in selected patients with peritoneal surface malignancies (PSM) of various tumour entities.
This treatment was not available in the Malaysian public health sector prior to 2018, due to lack of expertise, funding and accessibility.
We report our challenges in establishing the first such service.
